PCAS

Earnings Release • Jul 25, 2011

2 0 1 1 f i r s t - h a l f S a l e s

(in thousands of'euros)	H1-2011	H1-2010	% change	H2-2010
Sales	85 842	84 132	2,0%	74 379
including Pharmaceutical Synthesis	53 604	54 703	-2,0%	44 676
including Fine Specialty Chemicals	32 238	29 429	9,5%	29 703

(unaudited data)

The PCAS Group's consolidated Sales are up 2.0% at June 30th, 2011, compared with the same period of the previous year.

Pharmaceutical Synthesis

Business has been affected by the planned reduction in the contribution by the new contract between PCAS and Sanofi-Aventis, effective since May 31st, 2010.

Excluding this contract, the Exclusive and Non-Exclusive Pharma business is up 9.1% compared with the first half of 2010.

Fine Specialty Chemicals

The Fine Specialty Chemicals business achieved further growth in sales overall, coming in 9.5% higher than the first half of 2010.

The full consolidated half-year accounts will be reviewed and approved by the Board of Directors on September 7th.

This increase in sales over the first half of 2011 confirms the expected upturn in earnings following the disappointing performances seen in the second half of 2010.

Next date: consolidated half-year earnings on September 7th, 2011

About PCAS

PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

Longjumeau, July 25th, 2011